JP Morgan upgraded Cooper from Neutral to Overweight and set a new price target of $120.00 from $100.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/29/2024 | $115.00 → $120.00 | Overweight | Piper Sandler |
| 7/16/2024 | $107.00 → $115.00 | Hold → Buy | Jefferies |
| 3/19/2024 | $125.00 | Neutral → Buy | Redburn Atlantic |
| 3/13/2024 | $100.00 → $120.00 | Neutral → Overweight | JP Morgan |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/30/2023 | $380.00 | Buy | BofA Securities |
| 10/5/2023 | $390.00 → $343.00 | Overweight → Neutral | Redburn Atlantic |
| 5/30/2023 | $410.00 | Equal-Weight | Morgan Stanley |
SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2026064. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates thr
SAN RAMON, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that the company has been recognized as a Best Workplace for Innovators by Fast Company—a leading business media brand with an editorial focus on innovation—for creating a culture of employee development and belonging that inspires innovation and the development of new products and advocacy initiatives that aim to improve standard-of-care. This prestigious award recognizes organizations from around the world and across a variety of industries that demonstrate a commitment to encouraging and developing innovation at all levels. "Our work matters to us; you can see it in our culture and eve
The simplified insertion process is a milestone innovation for the market's leading hormone-free contraceptive, with an efficacy rate greater than 99% 1,2 CooperSurgical, a global leader in women's healthcare, today announced the launch of a new inserter designed for single-hand placement of Paragard®, which was recently approved by the U.S. Food and Drug Administration (FDA). The new single-hand inserter simplifies the placement process for healthcare providers, making Paragard an even more accessible contraceptive choice for both providers and patients. Paragard, the #1 prescribed copper intrauterine device (IUD), is a tried and true, non-hormonal contraceptive option with more than 30
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously
Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously
Redburn Atlantic upgraded Cooper from Neutral to Buy and set a new price target of $125.00
SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2026064. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates thr
SAN RAMON, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2024. Revenue increased 8% year-over-year to $1,002.8 million. CooperVision (CVI) revenue up 7% to $675.6 million, and CooperSurgical (CSI) revenue up 9% to $327.2 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.09 or 22% from last year's third quarter.Non-GAAP diluted EPS of $0.96, up $0.12 or 14% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Our
SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7528310. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two busine
Jefferies analyst Young Li upgrades Cooper Companies (NASDAQ:COO) from Hold to Buy and raises the price target from $107 to $115.
Piper Sandler analyst Jason Bednar maintains Cooper Companies (NASDAQ:COO) with a Overweight and maintains $115 price target.
Bears knocked on Wall Street’s door again Friday, sending large-cap tech stocks lower despite the Fed’s favorite inflation measure meeting expectations. Both the S&P 500 and the Nasdaq 100 index are set to end a 5-week winning streak as investors grow more cautious about the latest economic developments. In April 2024, the Personal Consumption Expenditure (PCE) price index held steady at 2.7% year-on-year, matching the previous month and forecasts. The annual core inflation rate also remained unchanged at 2.8%, in line with expectations. However, concerns arose from a deceleration in personal spending and income, raising fears that strong consumer momentum is waning. Additionally, t
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo
SAN RAMON, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also been appointed to serve on the Audit Committee and Corporate Governance and Nominating Committee when she joins the Board. "We are pleased to welcome Cindy to Cooper's Board of Directors," said Al White, President and CEO of CooperCompanies. "She is a highly successful executive with a strong strategic, financial, and operational background. We are confident that her business acumen and board experiences will benefit Cooper and our shareholders." Lucchese currentl